Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Home » Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®

GH AMEA on Social Media Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
U.S. FDA

Congratulations to #DaiichiSankyo and #AstraZeneca for its recent approval of ENHERTU® (fam-trastuzumab deruxtecan-nxki) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. https://lnkd.in/gBT2cFH

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us
Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU® - Guardant Health AMEA

Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Home » Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®

GH AMEA on Social Media Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
Congratulations to Daiichi Sankyo and AstraZeneca for its recent U.S. FDA approval of ENHERTU®
U.S. FDA

Congratulations to #DaiichiSankyo and #AstraZeneca for its recent approval of ENHERTU® (fam-trastuzumab deruxtecan-nxki) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. https://lnkd.in/gBT2cFH

Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at clientservices@guardantamea.com or contact us on WhatsApp: +65 8940 0360.

Guardant360®. Test. Take Action.

Open chat
Message us